Angiogenex Inc (AGGX) 0.2000 $AGGX Age Related Macular

New Post Public Reply Private Reply Replies (0) Message Board

Jun 9, 2016 at 9:02 PM

Angiogenex Inc (AGGX) 0.2000 $AGGX

Age Related Macular Degeneration Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xs8ntz/age_related) has announced the addition of the "Age Related Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Age Related Macular Degenerationand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Age Related Macular DegenerationOverview - Therapeutics Development - Pipeline Products for Age Related Macular Degeneration- Overview - Pipeline Products for Age Related Macular Degeneration- Comparative Analysis - Age Related Macular Degeneration- Therapeutics under Development by Companies - Age Related Macular Degeneration- Therapeutics under Investigation by Universities/Institutes - Age Related Macular Degeneration- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Age Related Macular Degeneration- Products under Development by Companies - Age Related Macular Degeneration- Products under Investigation by Universities/Institutes - Age Related Macular Degeneration- Companies Involved in Therapeutics Development Sample List of Companies - AC Immune SA - Allinky Biopharma - Amakem NV - Amarna Therapeutics B.V. - Amyndas Pharmaceuticals LLC - AngioGenex, Inc. - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporation - Avalanche Biotechnologies, Inc. - Clearside BioMedical, Inc. - Colby Pharmaceutical Company - Digna Biotech, S.L. - Dong-A Socio Group - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Foamix Pharmaceuticals Ltd. - Lead Discovery Center GmbH - LeadArtis S.L. - Mabion SA - MacuCLEAR, Inc. - Merz Pharma GmbH & Co. KgaA - Mitotech S.A. - Promedior, Inc. - Protelica Incorporated - pSivida Corp. - QLT Inc. - Quark Pharmaceuticals, Inc. - Ra Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RestorGenex Corporation - Ribomic Inc. - RXi Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/xs...ge_related
CLSD: 6.96 (-0.04), QLTI: 1.54 (-0.01), FOMX: 6.90 (-0.19), AAVL: 4.14 (-0.18), REGN: 381.08 (-7.89)

Global Breast Cancer Pipeline Review 2015
M2 - Tue Nov 03, 4:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/3xkrvl/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Breast Cancer diagnostic tests pipeline products. Scope - Extensive coverage of the Breast Cancer diagnostic tests under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Breast Cancer diagnostic tests and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Products under Development 4 Breast Cancer - Pipeline Products under Development by Companies 5 Breast Cancer Companies and Product Overview 6 Breast Cancer- Recent Developments 7 Appendix Companies Mentioned - 35 of the 150 Companies Featured - A&G Pharmaceutical, Inc. - Abbott Diagnostics - Abcodia Ltd. - Abviva, Inc. - Accelerated Medical Diagnostics - Acobiom - Advanced Cell Diagnostics, Inc. - Affichem SA - AIT Austrian Institute of Technology GmbH - Almac Diagnostics Limited - Amarantus Bioscience Holdings, Inc. - AngioGenex, Inc. - Armune BioScience, Inc. - Arno Therapeutics, Inc. - AroCell AB - ArtemixRx - Ascendant Diagnostics, LLC - Assurance Biosciences, Inc. - Atossa Genetics, Inc. - Autoimmune Technologies, LLC - Ayanda Biosystems S.A. - Becton, Dickinson and Company - Bio Gene Ltd. - BioAffinity Technologies, Inc. - Biocrates Life Sciences AG - Biodesix Inc. - BioMarCare Technologies Ltd. - BioMark Diagnostics Inc. - BioMark Technologies Inc. - BioMarker Strategies, LLC - bioMerieux S.A. - Biosceptre (Aust) Pty Ltd - BioSystems International - bioTheranostics, Inc. - Boston College For more information visit http://www.researchandmarkets.com/research/3x...ast_cancer
ATOS: 0.32 (-0.03)

Metastatic Breast Cancer - Pipeline Review, H1 2015 - Reviews Key Pipeline Products Under Drug Profile Section
M2 - Fri Aug 14, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kdtzh/metastatic_breast) has announced the addition of the "Metastatic Breast Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Breast Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Key Topics Covered: - Introduction - Metastatic Breast Cancer Overview - Therapeutics Development - Therapeutics under Development by Companies - Therapeutics under Investigation by Universities/Institutes - Pipeline Products Glance - Products under Development by Companies - Products under Investigation by Universities/Institutes - Companies Involved in Therapeutics Development - Therapeutics Assessment - Drug Profiles - Recent Pipeline Updates - Dormant Projects - Discontinued Products - Product Development Milestones Companies Mentioned - AbbVie Inc. - Advaxis, Inc. - Advenchen Laboratories, LLC - AlphaVax, Inc. - Amarna Therapeutics B.V. - Amgen Inc. - AngioGenex, Inc. - Aphios Corporation - arGEN-X BV - Aslan Pharmaceuticals Pte. Ltd. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Bayer AG - BIOCAD - Biocon Limited - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CASI Pharmaceuticals Inc. - Celgene Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Corcept Therapeutics Incorporated - Curadis GmbH - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - Dompe Farmaceutici S.p.A. - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/2k...tic_breast
ADXS: 8.82 (-0.19), BMRN: 82.94 (-1.16), CLDX: 4.32 (-0.40), AMGN: 156.78 (-1.22), LLY: 74.43 (-0.48), CASI: 1.39 (+0.07), BMY: 72.73 (-0.68), AZN: 28.96 (-0.68), AVEO: 1.06 (-0.01), ABBV: 60.75 (-0.98), CORT: 5.47 (-0.17), CELGZ: 1.46 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Jackson Wang's Fantasy IP Hits Hong Kong Stage

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

AI and Storytelling Make Waves in Science Education

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Endurance Energy's Modular Tech Revs Up Southeast Asia

Modular Solutions Steal the Show in Bangkok When a company draws 59,468 attendees from over 150 countries, folks pay attention—and that was exactly the scene at Gastech 2026 in Bangkok. The name buzzing on many lips? Endurance Energy. These guys showcased a fresh take on energy logistics with their skid-mounted liquefaction tech, turning heads with their Southeast Asia...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Timur Turlov Leads FIDE with Chess and Digital Focus

An Unpredicted Victory in Samarkand Well, color me surprised. Timur Turlov's made waves by clinching the role of FIDE President at the General Assembly in Samarkand. This one's quite the turn for the chess world—Kazakhstan’s own stepping up to run the whole show. This isn't just some ceremonial post either. Turlov, who's been pulling strings over at the Kazakhstan...

PACS Group Faces Legal Scrutiny: What to Watch

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...